Human innate immune cell crosstalk induces melanoma cell senescence

References

• Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol. 1998;28:4084–12. doi:10.1002/(SICI)1521-4141(199812)28:12<4084::AID-IMMU4084>3.0.CO;2-4.
   PubMed Web of Science ®Google Scholar
• Schakel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber EP. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity. 2002;17(3):289–301. doi:10.1016/S1074-7613(02)00393-X.
   PubMed Web of Science ®Google Scholar
• Schakel K, von Kietzell M, Hansel A, Ebling A, Schulze L, Haase M, Semmler C, Sarfati M, Barclay AN, Randolph GJ. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity. 2006;24:767–777. doi:10.1016/j.immuni.2006.03.020.
   PubMed Web of Science ®Google Scholar
• Schmitz M, Zhao S, Deuse Y, Schakel K, Wehner R, Wohner H, Hölig K, Wienforth F, Kiessling A, Bornhäuser M, et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol. 2005;174(7):4127–4134. doi:10.4049/jimmunol.174.7.4127.
   PubMed Web of Science ®Google Scholar
• Vermi W, Micheletti A, Lonardi S, Costantini C, Calzetti F, Nascimbeni R, Bugatti M, Codazzi M, Pinter PC, Schäkel K, et al. slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells. Nat Commun. 2014;5(1):3029. doi:10.1038/ncomms4029.
   PubMedGoogle Scholar
• Vermi W, Micheletti A, Finotti G, Tecchio C, Calzetti F, Costa S, Bugatti M, Calza S, Agostinelli C, Pileri S. slan(+) Monocytes and macrophages mediate CD20-dependent B-cell lymphoma elimination via ADCC and ADCP. Cancer Res. 2018;78:3544–3559. doi:10.1158/0008-5472.CAN-17-2344.
   PubMed Web of Science ®Google Scholar
• Micheletti A, Finotti G, Calzetti F, Lonardi S, Zoratti E, Bugatti M, Stefini S, Vermi W, Cassatella MA. slanDCs/M-DC8+ cells constitute a distinct subset of dendritic cells in human tonsils [corrected]. Oncotarget. 2016;7:161–175. doi:10.18632/oncotarget.6660.
   PubMedGoogle Scholar
• Wehner R, Lobel B, Bornhauser M, Schakel K, Cartellieri M, Bachmann M, Rieber EP, Schmitz M. Reciprocal activating interaction between 6-sulfo LacNAc + dendritic cells and NK cells. Int J Cancer. 2009;124(2):358–366. doi:10.1002/ijc.23962.
   PubMed Web of Science ®Google Scholar
• Schmitz M, Zhao S, Schakel K, Bornhauser M, Ockert D, Rieber EP. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood. 2002;100:1502–1504. doi:10.1182/blood.V100.4.1502.h81602001502_1502_1504.
   PubMed Web of Science ®Google Scholar
• Tufa DM, Ahmad F, Chatterjee D, Ahrenstorf G, Schmidt RE, Jacobs R. IL-1beta limits the extent of human 6-sulfo LacNAc dendritic cell (slanDC)-mediated NK cell activation and regulates CD95-induced apoptosis. Cell Mol Immunol. 2017;14:976–985. doi:10.1038/cmi.2016.17.
   PubMed Web of Science ®Google Scholar
• Hanna RN, Cekic C, Sag D, Tacke R, Thomas GD, Nowyhed H, Herrley E, Rasquinha N, McArdle S, Wu R. Patrolling monocytes control tumor metastasis to the lung. Science. 2015;350(6263):985–990. doi:10.1126/science.aac9407.
   PubMed Web of Science ®Google Scholar
• Narasimhan PB, Eggert T, Zhu YP, Marcovecchio P, Meyer MA, Wu R, Hedrick CC. Patrolling monocytes control NK cell expression of activating and stimulatory receptors to curtail lung metastases. J Immunol. 2020;204(1):192–198. doi:10.4049/jimmunol.1900998.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Carrega P, Dondero A, Bellora F, Casu B, Regis S, Ferlazzo G, Bottino C. Molecular mechanisms directing migration and retention of natural killer cells in human tissues. Front Immunol. 2018;9:2324. doi:10.3389/fimmu.2018.02324.
   PubMed Web of Science ®Google Scholar
• Lima M, Leander M, Santos M, Santos AH, Lau C, Queiros ML, Gonçalves M, Fonseca S, Moura J, Teixeira MDA. Chemokine receptor expression on normal blood CD56 + NK-cells elucidates cell partners that comigrate during the innate and adaptive immune responses and identifies a transitional NK-cell population. J Immunol Res. 2015;2015:839684. doi:10.1155/2015/839684.
   PubMed Web of Science ®Google Scholar
• Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH. Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. Oncoimmunology. 2012;1(4):448–457. doi:10.4161/onci.19788.
   PubMed Web of Science ®Google Scholar
• Barrow AD, Edeling MA, Trifonov V, Luo J, Goyal P, Bohl B, Bando JK, Kim AH, Walker J, Andahazy M. Natural killer cells control tumor growth by sensing a growth factor. Cell. 2018;172(3):e19. doi:10.1016/j.cell.2017.11.037.
   Web of Science ®Google Scholar
• Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593–602. doi:10.1016/S0092-8674(00)81902-9.
   PubMed Web of Science ®Google Scholar
• Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109(3):335–346. doi:10.1016/S0092-8674(02)00734-1.
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497–1501. doi:10.1126/science.282.5393.1497.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhou M, Lin F, Liu D, Hong W, Lu L, Zhu Y, Xu A. Interferon-gamma induces senescence in normal human melanocytes. PLoS One. 2014;9:e93232. doi:10.1371/journal.pone.0093232.
   PubMed Web of Science ®Google Scholar
• Kumar PS, Shiras A, Das G, Jagtap JC, Prasad V, Shastry P. Differential expression and role of p21cip/waf1 and p27kip1 in TNF-alpha-induced inhibition of proliferation in human glioma cells. Mol Cancer. 2007;6:42. doi:10.1186/1476-4598-6-42.
   PubMed Web of Science ®Google Scholar
• Kandhaya-Pillai R, Miro-Mur F, Alijotas-Reig J, Tchkonia T, Kirkland JL, Schwartz S. TNFalpha-senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion. Aging (Albany NY). 2017;9:2411–2435. doi:10.18632/aging.101328.
   PubMedGoogle Scholar
• Wieder T, Brenner E, Braumuller H, Bischof O, Rocken M. Cytokine-induced senescence for cancer surveillance. Cancer Metastasis Rev. 2017;36:357–365. doi:10.1007/s10555-017-9667-z.
   PubMed Web of Science ®Google Scholar
• Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494(7437):361–365. doi:10.1038/nature11824.
   PubMed Web of Science ®Google Scholar
• Richardson RM, Pridgen BC, Haribabu B, Ali H, Snyderman R. Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation. J Biol Chem. 1998;273(37):23830–23836. doi:10.1074/jbc.273.37.23830.
   PubMed Web of Science ®Google Scholar
• Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol. 2009;183:3425–3432. doi:10.4049/jimmunol.0900305.
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92:9363–9367. doi:10.1073/pnas.92.20.9363.
   PubMed Web of Science ®Google Scholar
• Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. doi:10.1146/annurev-pathol-121808-102144.
   PubMed Web of Science ®Google Scholar
• Collison JL, Carlin LM, Eichmann M, Geissmann F, Peakman M. Heterogeneity in the locomotory behavior of human monocyte subsets over human vascular endothelium in vitro. J Immunol. 2015;195:1162–1170. doi:10.4049/jimmunol.1401806.
   PubMed Web of Science ®Google Scholar
• Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33:375–386. doi:10.1016/j.immuni.2010.08.012.
   PubMed Web of Science ®Google Scholar
• Bellora F, Castriconi R, Dondero A, Carrega P, Mantovani A, Ferlazzo G, Moretta A, Bottino C. Human NK cells and NK receptors. Immunol Lett. 2014;161(2):168–173. doi:10.1016/j.imlet.2013.12.009.
   PubMed Web of Science ®Google Scholar
• Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V, Cipollone G, Navarra G, Mingari MC, Moretta L. CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol. 2014;192:3805–3815. doi:10.4049/jimmunol.1301889.
   PubMed Web of Science ®Google Scholar
• Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, Rachmilewitz J. Characterization of tumor infiltrating natural killer cell subset. Oncotarget. 2015;6:13835–13843. doi:10.18632/oncotarget.3453.
   PubMed Web of Science ®Google Scholar
• Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22(15):3924–3936. doi:10.1158/1078-0432.CCR-15-2463.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Yamamoto T, Hirai H, Hanada K, Kiyasu Y, Nishikawa G, Mizuno R, Inamoto S, Itatani Y, Sakai Y, et al. Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via the cxcl1/8-cxcr2 axis. Clin Cancer Res. 2019;25:2887–2899. doi:10.1158/1078-0432.CCR-18-3684.
   PubMed Web of Science ®Google Scholar
• Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra67. doi:10.1126/scitranslmed.3007974.
   PubMed Web of Science ®Google Scholar
• Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis E Sousa C. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):e14. doi:10.1016/j.cell.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 1997;57:4868–4875.
   PubMed Web of Science ®Google Scholar
• Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998;16:311–320. doi:10.1038/sj.onc.1201543.
   PubMed Web of Science ®Google Scholar
• Barr AR, Cooper S, Heldt FS, Butera F, Stoy H, Mansfeld J, Novák B, Bakal C. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat Commun. 2017;8(1):14728. doi:10.1038/ncomms14728.
   PubMed Web of Science ®Google Scholar
• Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang T-W, Lasitschka F, Andrulis M. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):978–990. doi:10.1038/ncb2784.
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656–660. doi:10.1038/nature05529.
   PubMed Web of Science ®Google Scholar
• Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce J, Krizhanovsky V. Non-cell-autonomous tumor suppression by p53. Cell. 2013;153(2):449–460. doi:10.1016/j.cell.2013.03.020.
   PubMed Web of Science ®Google Scholar
• Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell. 2016;30(4):533–547. doi:10.1016/j.ccell.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Kim YH, Choi YW, Lee J, Soh EY, Kim JH, Park TJ. Senescent tumor cells lead the collective invasion in thyroid cancer. Nat Commun. 2017;8:15208. doi:10.1038/ncomms15208.
   PubMed Web of Science ®Google Scholar
• Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 2007;67:3117–3126. doi:10.1158/0008-5472.CAN-06-3452.
   PubMed Web of Science ®Google Scholar
• Angelini PD, Zacarias FMF, Pedersen K, Parra-Palau JL, Guiu M, Bernado Morales C, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 2013;73:450–458. doi:10.1158/0008-5472.CAN-12-2301.
   PubMed Web of Science ®Google Scholar
• Milanovic M, Fan DNY, Belenki D, Dabritz JHM, Zhao Z, Yu Y, Dörr JR, Dimitrova L, Lenze D, Monteiro Barbosa IA, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553(7686):96–100. doi:10.1038/nature25167.
   PubMed Web of Science ®Google Scholar
• Yang L, Fang J, Chen J. Tumor cell senescence response produces aggressive variants. Cell Death Discov. 2017;3(1):17049. doi:10.1038/cddiscovery.2017.49.
   PubMedGoogle Scholar
• Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med. 2013;210:2057–2069. doi:10.1084/jem.20130783.
   PubMed Web of Science ®Google Scholar
• Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011;71:5998–6009. doi:10.1158/0008-5472.CAN-10-3211.
   PubMed Web of Science ®Google Scholar
• Sagiv A, Burton DG, Moshayev Z, Vadai E, Wensveen F, Ben-Dor S, Golani O, Polic B, Krizhanovsky V. NKG2D ligands mediate immunosurveillance of senescent cells. Aging (Albany NY). 2016;8(2):328–344. doi:10.18632/aging.100897.
   PubMedGoogle Scholar
• Ellis LZ, Cohen JL, High W, Stewart L. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature. Dermatol Surg. 2012;38:937–946. doi:10.1111/j.1524-4725.2012.02362.x.
   PubMed Web of Science ®Google Scholar
• Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000;43:555–556.
   PubMed Web of Science ®Google Scholar
• Fan Q, Cohen S, John B, Riker AI. Melanoma in situ treated with topical imiquimod for management of persistently positive margins: a review of treatment methods. Ochsner J. 2015;15:443–447.
   PubMed Web of Science ®Google Scholar
• Tio D, van Montfrans C, Ruijter CGH, Hoekzema R, Bekkenk MW. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. Acta Derm Venereol. 2019;99:884–888. doi:10.2340/00015555-3241.
   PubMed Web of Science ®Google Scholar